FDA label
What is Vyzulta used for?
Vyzulta contains latanoprostene bunod. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “VYZULTA ®(latanoprostene bunod ophthalmic solution) 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Vyzulta?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Vyzulta, solution/ drops
Indications and Usage, quoted from the label by Bausch & Lomb Incorporated (NDA207795). Cross-references to other label sections are left out.
VYZULTA ®(latanoprostene bunod ophthalmic solution) 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Source: DailyMed label, set id 60ce7900-a677-4fc2-88d0-1603baa9dbd4, version 7, effective February 27, 2024. NDC 24208-504, one of 1 listing for this product.
Questions
What is Vyzulta used for?
The FDA label says: “VYZULTA ®(latanoprostene bunod ophthalmic solution) 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.”
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.